ObjectiveThis study aimed to analyze the clinical outcomes after revascularization for CLTI in patients aged ≥80 years and <80 years. MethodsWe retrospectively analyzed multicenter data of 789 patients who underwent infrainguinal revascularization for CLTI between 2015 and 2021. The endpoints were 2-year overall survival (OS), amputation free survival (AFS), limb salvage (LS), and postoperative complications. ResultsA total of 90 patients aged ≥80 years and 200 patients aged <80 years underwent bypass surgery (BSX), and 205 patients aged ≥80 years and 294 patients aged <80 years underwent endovascular therapy (EVT). Before the propensity score matching (PSM), multivariate analyses showed that age ≥80 years, lower body mass index (BMI) and serum albumin levels, nonambulatory status, and end-stage renal disease were independent risk factors for 2-year mortality in the BSX and EVT groups. After PSM, the 2-year OS was better in the <80 years cohort than in the ≥80 years cohort in both the BSX and EVT groups (P = .018 and P = .035, respectively). There was no difference in the 2-year LS rates between the <80 years and the ≥80 years cohorts in both the BSX and EVT groups (P = .621 and P = .287, respectively). According to the number of risk factors, except for age ≥80 years, there was no difference in the 2-year AFS rates between the <80 years and ≥80 years cohorts for the BSX and EVT groups with 0–1 risk factor (P = .957 and P = .655, respectively). However, the 2-year AFS rate was poor, especially in the ≥80 years cohort in the BSX with 2–4 risk factors (P = .015). The Clavien–Dindo ≥IV complication rates tended to be higher in the ≥80 years cohort than in the <80 years cohort only in the BSX with 2–4 risk factors (P = .056). ConclusionsPatients with CLTI aged ≥80 years had poorer OS than those aged <80. However, there was no difference in LS between the ≥80 years and <80 years cohorts in both the BSX and EVT groups. Although age ≥80 years was associated with poorer OS, patients with 0–1 risk factor may benefit from revascularization, including BSX, because no difference was observed in AFS or Clavien–Dindo ≥IV complications.
Read full abstract